본문 바로가기
KERD
논문KCI 등재

The role of inflammation in diabetic kidney disease

Su Woong Jung|Ju-Young Moon
대한내과학회 (The Korean Association Of Internal Medicine)|2021.07|The Korean Journal of Internal Medicine|제36권 제4호|pp. 753-766|DOI https://doi.org/10.3904/kjim.2021.174

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

InflammationPathogenesisDiabetic nephropathies
주제분류내과학

초록

Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease for over 20 years. Yet, over these two decades, the clinical approach to this condition has not much improved beyond the administration of glucose-lowering agents, renin-angiotensin-aldosterone system blockers for blood pressure control, and lipid-lowering agents. The proportion of diabetic patients who develop DKD and progress to end-stage renal disease has remained nearly the same. This unmet need for DKD treatment is caused by the complex pathophysiology of DKD, and the difficulty of translating treatment from bench to bed, which further adds to the growing argument that DKD is not a homogeneous disease. To better capture the full spectrum of DKD in our design of treatment regimens, we need improved diagnostic tools that can better distinguish the subgroups within the condition. For instance, DKD is typically placed in the broad category of a non-inflammatory kidney disease. However, genome-wide transcriptome analysis studies consistently indicate the inflammatory signaling pathway activation in DKD. This review will utilize human data in discussing the potential for redefining the role of inflammation in DKD. We also comment on the therapeutic potential of targeted anti-inflammatory therapy for DKD.

Abstract

Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease for over 20 years. Yet, over these two decades, the clinical approach to this condition has not much improved beyond the administration of glucose-lowering agents, renin-angiotensin-aldosterone system blockers for blood pressure control, and lipid-lowering agents. The proportion of diabetic patients who develop DKD and progress to end-stage renal disease has remained nearly the same. This unmet need for DKD treatment is caused by the complex pathophysiology of DKD, and the difficulty of translating treatment from bench to bed, which further adds to the growing argument that DKD is not a homogeneous disease. To better capture the full spectrum of DKD in our design of treatment regimens, we need improved diagnostic tools that can better distinguish the subgroups within the condition. For instance, DKD is typically placed in the broad category of a non-inflammatory kidney disease. However, genome-wide transcriptome analysis studies consistently indicate the inflammatory signaling pathway activation in DKD. This review will utilize human data in discussing the potential for redefining the role of inflammation in DKD. We also comment on the therapeutic potential of targeted anti-inflammatory therapy for DKD.

참고문헌 (124)

  1. Upadhaya S, "Immuno-oncology drug development forges on despite COVID-19", Nat Rev Drug Discov, 19, pp.751~752 (2020)
  2. National Kidney Foundation, "KDOQI clinical practice guideline for diabetes and CKD : 2012 update", Am J Kidney Dis, 60, pp.850~886 (2012)
  3. American Diabetes Association, "Standards of medical care in diabetes : 2020. Abridged for primary care providers", Clin Diabetes, 38, pp.10~38 (2020)
  4. Kipyo Kim, "Current findings of kidney biopsy including nephropathy associated with hypertension and diabetes mellitus in Korea", The Korean Journal of Internal Medicine, 35(5), pp.1173~1187 (2020), 대한내과학회[DOI]
  5. Oh Kook-Hwan, "The KNOW-CKD Study: What we have learned about chronic kidney diseases", Kidney Research and Clinical Practice, 39(2), pp.121~135 (2020), 대한신장학회[DOI]
  6. Tervaert TW, "Pathologic classification of diabetic nephropathy", J Am Soc Nephrol, 21, pp.556~563 (2010)
  7. Alicic RZ, "Diabetic kidney disease : challenges, progress, and possibilities", Clin J Am Soc Nephrol, 12, pp.2032~2045 (2017)
  8. Sehoon Park, "Characteristics of kidney transplantation recipients over time in South Korea", The Korean Journal of Internal Medicine, 35(6), pp.1457~1467 (2020), 대한내과학회[DOI]
  9. Jeong Seon Yoo, "Predictive costs in medical care for Koreans with metabolic syndrome from 2009 to 2013 based on the National Health Insurance claims dataset", The Korean Journal of Internal Medicine, 35(4), pp.936~945 (2020), 대한내과학회[DOI]
  10. 임태훈, "Patterns in renal diseases diagnosed by kidney biopsy: A single-center experience", Kidney Research and Clinical Practice, 39(1), pp.60~69 (2020), 대한신장학회[DOI]
  11. 이준영, "Adiponectin for the treatment of diabetic nephropathy", The Korean Journal of Internal Medicine, 34(3), pp.480~491 (2019), 대한내과학회[DOI]
  12. Sugahara M, "Update on diagnosis, pathophysiology, and management of diabetic kidney disease", Nephrology(Carlton), 26, pp.491~500 (2021)
  13. Tomoko Honda, "The role of oxidative stress and hypoxia in renal disease", Kidney Research and Clinical Practice, 38(4), pp.414~426 (2019), 대한신장학회[DOI]
  14. Divya Bhatia, "Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches", Kidney Research and Clinical Practice, 39(3), pp.244~258 (2020), 대한신장학회[DOI]
  15. Sho Hasegawa, "Neuroimmune interactions and kidney disease", Kidney Research and Clinical Practice, 38(3), pp.282~294 (2019), 대한신장학회[DOI]
  16. Woroniecka KI, "Transcriptome analysis of human diabetic kidney disease", Diabetes, 60, pp.2354~2369 (2011)
  17. Wilson PC, "The single-cell transcriptomic landscape of early human diabetic nephropathy", Proc Natl Acad Sci USA, 116, pp.19619~19625 (2019)
  18. Kodera R, "Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes", Diabetologia, 54, pp.965~978 (2011)
  19. Katagiri D, "Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection", J Am Soc Nephrol, 24, pp.2034~2043 (2013)
  20. Fujita H, "The protective roles of GLP-1R signaling in diabetic nephropathy : possible mechanism and therapeutic potential", Kidney Int, 85, pp.579~589 (2014)
  21. Heerspink HJ, "Canagliflozin reduces inflammation and fibrosis biomarkers : a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease", Diabetologia, 62, pp.1154~1166 (2019)
  22. Lin M, "Toll-like receptors : sensing and reacting to diabetic injury in the kidney", Nephrol Dial Transplant, 29, pp.746~754 (2014)
  23. Rock KL, "The sterile inflammatory response", Annu Rev Immunol, 28, pp.321~342 (2010)
  24. Devaraj S, "Increased Toll-like receptor(TLR)2 and TLR4 expression in monocytes from patients with type 1 diabetes : further evidence of a proinflammatory state", J Clin Endocrinol Metab, 93, pp.578~583 (2008)
  25. Devaraj S, "Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes", Diabetologia, 52, pp.1665~1668 (2009)
  26. Dasu MR, "Increased Toll-like receptor(TLR)activation and TLR ligands in recently diagnosed type 2 diabetic subjects", Diabetes Care, 33, pp.861~868 (2010)
  27. Lin M, "Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy", J Am Soc Nephrol, 23, pp.86~102 (2012)
  28. Verzola D, "Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria", Kidney Int, 86, pp.1229~1243 (2014)
  29. Kanneganti TD, "Intracellular NOD-like receptors in host defense and disease", Immunity, 27, pp.549~559 (2007)
  30. Niemir ZI, "Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides", Kidney Int, 52, pp.393~403 (1997)
  31. Wang S, "Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation", Cell Death Dis, 8, pp.e2937~ (2017)
  32. Heid ME, "Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation", J Immunol, 191, pp.5230~5238 (2013)
  33. Kersse K, "NOD-like receptors and the innate immune system : coping with danger, damage and death", Cytokine Growth Factor Rev, 22, pp.257~276 (2011)
  34. Martinon F, "Gout-associated uric acid crystals activate the NALP3 inflammasome", Nature, 440, pp.237~241 (2006)
  35. Shah A, "Thioredoxin-interacting protein mediates high glucose-induced reactive oxygen species generation by mitochondria and the NADPH oxidase, Nox4, in mesangial cells", J Biol Chem, 288, pp.6835~6848 (2013)
  36. Ludwig-Portugall I, "An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice", Kidney Int, 90, pp.525~539 (2019)
  37. Lau A, "Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury", J Clin Invest, 128, pp.2894~2913 (2018)
  38. Shahzad K, "Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy", Kidney Int, 87, pp.74~84 (2015)
  39. Kim SM, "Inflammasome-independent role of NLRP3 mediates mitochondrial regulation in renal injury", Front Immunol, 9, pp.2563~ (2018)
  40. Zhang C, "Activation of NOD-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia", Hypertension, 60, pp.154~162 (2012)
  41. Shoelson SE, "Inflammation and insulin resistance", J Clin Invest, 11, pp.1793~1801 (2006)
  42. Lee HM, "Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes", Diabetes, 62, pp.194~204 (2013)
  43. Martini S, "Defining human diabetic nephropathy on the molecular level : integration of transcriptomic profiles with biological knowledge", Rev Endocr Metab Disord, 9, pp.267~274 (2008)
  44. Balasubramaniam G, "Improved renal function in diabetic patients with acute gout treated with anakinra", Kidney Int, 88, pp.195~196 (2015)
  45. Furuta T, "The role of macrophages in diabetic glomerulosclerosis", Am J Kidney Dis, 21, pp.480~485 (1993)
  46. Nguyen D, "Macrophage accumulation in human progressive diabetic nephropathy", Nephrology(Carlton), 11, pp.226~231 (2006)
  47. Susztak K, "Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy", Diabetes, 55, pp.225~233 (2006)
  48. Har R, "The effect of renal hyperfiltration on urinary inflammatory cytokines", chemokines in patients with uncomplicated type 1 diabetes mellitus, 2013, pp.56, 1166~1173
  49. Nitta K, "Serum levels of macrophage colony-stimulating factor and aortic calcification in hemodialysis patients", Am J Nephrol, 21, pp.465~470 (2001)
  50. Moore KJ, "TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease", J Immunol, 157, pp.427~432 (1996)
  51. Jang MH, "Distinct in vivo roles of colony-stimulating factor-1 isoforms in renal inflammation", J Immunol, 177, pp.4055~4063 (2006)
  52. Lim AK, "Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db", db mice, 2009, pp.52, 1669~1679
  53. Chow FY, "Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db", db mice, 2005, pp.16, 1711~1722
  54. Chow FY, "Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db", db mice, 2007, pp.50, 471~480
  55. Chow FY, "Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice", Kidney Int, 69, pp.73~80 (2006)
  56. Nelson PJ, "The renal mononuclear phagocytic system", J Am Soc Nephrol, 23, pp.194~203 (2012)
  57. Navarro-Gonzalez JF, "The role of inflammatory cytokines in diabetic nephropathy", J Am Soc Nephrol, 19, pp.433~442 (2008)
  58. Navarro-Gonzalez JF, "Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy", Nat Rev Nephrol, 7, pp.327~340 (2011)
  59. Milas O, "Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients", J Diabetes Complications, 34, pp.107479~ (2020)
  60. Moriwaki Y, "Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus : relationship with diabetic nephropathy", Metabolism, 52, pp.605~608 (2003)
  61. Wong CK, "Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy", Clin Exp Immunol, 149, pp.123~131 (2007)
  62. Miyauchi K, "Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy : TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells", Diabetes Res Clin Pract, 83, pp.190~199 (2009)
  63. Araki S, "Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes : an observational follow-up study", Diabetologia, 50, pp.867~873 (2007)
  64. Pickup JC, "Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes", Life Sci, 67, pp.291~300 (2000)
  65. Sekizuka K, "Detection of serum IL-6 in patients with diabetic nephropathy", Nephron, 68, pp.284~285 (1994)
  66. Dalla Vestra M, "Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes", J Am Soc Nephrol, 16(Suppl 1), pp.S78~S82 (2005)
  67. Shikano M, "Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy", Nephron, 85, pp.81~85 (2000)
  68. Sangoi MB, "Urinary inflammatory cytokines as indicators of kidney damage in type 2 diabetic patients", Clin Chim Acta, 460, pp.178~183 (2016)
  69. Suzuki D, "In situ hybridization of interleukin 6 in diabetic nephropathy", Diabetes, 44, pp.1233~1238 (1995)
  70. Park J, "Functional methylome analysis of human diabetic kidney disease", JCI Insight, 4, pp.e128886~ (2019)
  71. Navarro JF, "Renal pro-inflammatory cytokine gene expression in diabetic nephropathy : effect of angiotensin-converting enzyme inhibition and pentoxifylline administration", Am J Nephrol, 26, pp.562~570 (2006)
  72. Navarro JF, "Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus", Am J Kidney Dis, 42, pp.53~61 (2003)
  73. Pedigo CE, "Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury", J Clin Invest, 126, pp.3336~3350 (2016)
  74. Niewczas MA, "Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes", Clin J Am Soc Nephrol, 4, pp.62~70 (2009)
  75. Coca SG, "Plasma biomarkers and kidney function decline in early and established diabetic kidney disease", J Am Soc Nephrol, 28, pp.2786~2793 (2017)
  76. Baharlou R, "Elevated levels of T-helper 17-associated cytokines in diabetes type 1 patients. Indicators for following the course of disease", Immunol Invest, 45, pp.641~651 (2016)
  77. Vasanthakumar R, "Serum IL-9, IL-17, and TGF-β levels in subjects with diabetic kidney disease(CURES-134)", Cytokine, 72, pp.109~112 (2015)
  78. Kuo HL, "IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy", Nephrol Dial Transplant, 33, pp.248~256 (2018)
  79. Ruster C, "The role of chemokines and chemokine receptors in diabetic nephropathy", Front Biosci, 13, pp.944~955 (2008)
  80. Tesch GH, "MCP-1", CCL2 : a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy, 2008, pp.294, F697~F701
  81. Ju-young Moon, "Association of Polymorphisms in Monocyte Chemoattractant Protein-1Promoter with Diabetic Kidney Failure in Korean Patients with Type2 Diabetes Mellitus", Journal of Korean Medical Science, 22(5), pp.810~814 (2007), 대한의학회
  82. Tashiro K, "Urinary levels of monocyte chemoattractant protein-1(MCP-1)and interleukin-8(IL-8), and renal injuries in patients with type 2diabetic nephropathy", J Clin Lab Anal, 16, pp.1~4 (2002)
  83. Wada T, "Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy", Kidney Int, 58, pp.1492~1499 (2000)
  84. Tarabra E, "Effect of the monocyte chemoattractant protein-1", CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes, 2009, pp.58, 2109~2118
  85. Lee EY, "The monocyte chemoattractant protein-1", CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability, 2009, pp.297, F85~F94
  86. Herder C, "Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes : results from the Finnish Diabetes Prevention Study", Diabetes, 55, pp.2340~2346 (2006)
  87. Mezzano S, "NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy", Nephrol Dial Transplant, 19, pp.2505~2512 (2004)
  88. Schinzari F, "Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment", Vascul Pharmacol, 128-129, pp.106676~ (2020)
  89. Shah R, "Serum fractalkine(CX3CL1)and cardiovascular outcomes and diabetes : findings from the Chronic Renal Insufficiency Cohort(CRIC)Study", Am J Kidney Dis, 66, pp.266~273 (2015)
  90. Sindhu S, "Increased circulatory levels of fractalkine(CX3CL1)are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes", J Diabetes Metab Disord, 16, pp.15~ (2017)
  91. Williams A, "Increased circulating cytokine levels in African American women with obesity and elevated HbA1c", Cytokine, 128, pp.154989~ (2020)
  92. Hajishengallis G, "Novel mechanisms and functions of complement", Nat Immunol, 18, pp.1288~1298 (2017)
  93. Tang S, "Contribution of renal secreted complement C3 to the circulating pool in humans", J Immunol, 162, pp.4336~4341 (1999)
  94. Biancone L, "Alternative pathway activation of complement by cultured human proximal tubular epithelial cells", Kidney Int, 45, pp.451~460 (1994)
  95. Flyvbjerg A, "The role of the complement system in diabetic nephropathy", Nat Rev Nephrol, 13, pp.311~318 (2017)
  96. Rasmussen KL, "Complement C3 and risk of diabetic microvascular disease : a cohort study of 95202 individuals from the general population", Clin Chem, 64, pp.1113~1124 (2018)
  97. Sircar M, "Complement 7 is up-regulated in human early diabetic kidney disease", Am J Pathol, 188, pp.2147~2154 (2018)
  98. Hansen TK, "Mannose-binding lectin and mortality in type 2 diabetes", Arch Intern Med, 166, pp.2007~2013 (2006)
  99. Hansen TK, "Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes", Diabetologia, 53, pp.1517~1524 (2010)
  100. Vaisar T, "Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes", Diabetes Care, 41, pp.2361~2369 (2018)
  101. Sun ZJ, "Complement deposition on renal histopathology of patients with diabetic nephropathy", Diabetes Metab, 45, pp.363~368 (2019)
  102. Yiu WH, "Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy", Nephrol Dial Transplant, 33, pp.1323~1332 (2018)
  103. Anand G, "Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2cytokine profile in patients with diabetic nephropathy(CURES-134)", Int J Clin Exp Pathol, 7, pp.8008~8015 (2014)
  104. Zeng C, "The imbalance of Th17", Th1, J Mol Med(Berl), pp.2012, 90[DOI]
  105. Moon JY, "Aberrant recruitment and activation of T cells in diabetic nephropathy", Am J Nephrol, 35, pp.164~174 (2012)
  106. Moriya R, "Juxtaglomerular apparatus T-cell infiltration affects glomerular structure in type 1 diabetic patients", Diabetologia, 47, pp.82~88 (2004)
  107. Paulsen EP, "Juxtaglomerular body abnormalities in youth-onset diabetic subjects", Kidney Int, 45, pp.1132~1139 (1994)
  108. Aviado DM, "Pentoxifylline : a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects", Pharmacotherapy, 4, pp.297~307 (1984)
  109. Rodriguez-Moran M, "Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes", Curr Diabetes Rev, 4, pp.55~62 (2008)
  110. Bhanot S, "Pentoxifylline for diabetic nephropathy:an important opportunity to re-purpose an old drug?", Curr Hypertens Rep, 18, pp.8~ (2016)
  111. Donate-Correa J, "Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons", J Clin Med, 8, pp.287~ (2019)
  112. Navarro-Gonzalez JF, "Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease : the PREDIAN trial", J Am Soc Nephrol, 26, pp.220~229 (2015)
  113. Levey AS, "The definition, classification, and prognosis of chronic kidney disease:a KDIGO Controversies Conference report", Kidney Int, 80, pp.17~28 (2011)
  114. Tuttle KR, "JAK1", JAK2inhibition by baricitinib in diabetic kidney disease : results from a phase 2 randomized controlled clinical trial, 2018, pp.33, 1950~1959
  115. Yang M, "ASK1-JNK signaling cascade mediates Ad-ST13-induced apoptosis in colorectal HCT116 cells", J Cell Biochem, 110, pp.581~588 (2010)
  116. Nishitoh H, "ASK1 is essential for JNK", SAPK activation by TRAF2, 1998, pp.2, 389~395
  117. Chertow GM, "Effects of selonsertib in patients with diabetic kidney disease", J Am Soc Nephrol, 30, pp.1980~1990 (2019)
  118. Menne J, "C-C motif-ligand 2inhibition with emapticap pegol(NOX-E36)in type 2 diabetic patients with albuminuria", Nephrol Dial Transplant, 32, pp.307~315 (2017)
  119. de Zeeuw D, "The effect of CCR2inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy : a randomised trial", Lancet Diabetes Endocrinol, 3, pp.687~696 (2015)
  120. Salmi M, "Induction and function of vascular adhesion protein-1 at sites of inflammation", J Exp Med, 178, pp.2255~2260 (1993)
  121. Smith DJ, "Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule", J Exp Med, 188, pp.17~27 (1998)
  122. Wang SH, "Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in cholesterol-fed New Zealand white rabbits", Sci Rep, 8, pp.9249~ (2018)
  123. de Zeeuw D, "Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease(ALBUM) : a randomised, placebo-controlled, phase 2 trial", Lancet Diabetes Endocrinol, 6, pp.925~933 (2018)
  124. Mazidi M, "Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus : a systematic review and meta-analysis of randomized controlled trials", J Diabetes Complications, 31, pp.1237~1242 (2017)

관련 논문AI추천

New therapeutic agents in diabetic nephropathy김예니, 박철휘대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제1호Treatment of diabetic kidney disease: current and future targets김미경대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제4호당뇨병성 신증 연구의 최신지견이은영, 정춘희대한내과학회 · 대한내과학회지2008 · 제75권 제6호Steps to understanding diabetes kidney disease: a focus on metabolomics송상헌, Hyo Jin Kim대한내과학회 · The Korean Journal of Internal Medicine2024 · 제39권 제6호Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs김상수, 김효진, 송상헌대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제3호Adiponectin for the treatment of diabetic nephropathy김재석, 양재원, 이준영, 최승옥, 한병근대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제3호

이 간행물의 다른 논문 (28건)

Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patientsKook-Hwan Oh, 박혜인, Yong-Chul Kim, Yun Kyu Oh, Hyunjin Ryupp. 767-779Blood pressure control in patients with chronic kidney diseaseSeung Hyeok Han, Jee Young Leepp. 780-794How important is dietary management in chronic kidney disease progression? A role for low protein dietsGang-Jee Ko, Kamyar Kalantar-Zadehpp. 795-806Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020Il Ju Choi, Jae Gyu Kim, Seon-Young Park, Hye-Kyung Jung, Woon Geon Shin, Hyo-Joon Yang, 김지현, 임현철, 이용찬, Sung Eun Kim, Jae Myung Park, Miyoung Choi, Su Youn Nam, Seung Joo Kang, Cheol Min Shinpp. 807-838Risk-stratified colorectal cancer screening for optimal use of colonoscopy resourcesDong-Hoon Yangpp. 839-841
원문 보기